» Articles » PMID: 36851796

Low Prevalence of SARS-CoV-2 Antibodies in Canine and Feline Serum Samples Collected During the COVID-19 Pandemic in Hong Kong and Korea

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide since its emergence in 2019. Knowing the potential capacity of the virus to adapt to other species, the serological surveillance of SARS-CoV-2 infection in susceptible animals is important. Hong Kong and Seoul are two of Asia's most densely populated urban cities, where companion animals often live in close contact with humans. Sera collected from 1040 cats and 855 dogs during the early phase of the pandemic in Hong Kong and Seoul were tested for SARS-CoV-2 antibodies using an ELISA that detects antibodies against the receptor binding domain of the viral spike protein. Positive sera were also tested for virus neutralizing antibodies using a surrogate virus neutralization (sVNT) and plaque reduction neutralization test (PRNT). Among feline sera, 4.51% and 2.54% of the samples from Korea and Hong Kong, respectively, tested ELISA positive. However, only 1.64% of the samples from Korea and 0.18% from Hong Kong tested positive by sVNT, while only 0.41% of samples from Korea tested positive by PRNT. Among canine samples, 4.94% and 6.46% from Korea and Hong Kong, respectively, tested positive by ELISA, while only 0.29% of sera from Korea were positive on sVNT and no canine sera tested positive by PRNT. These results confirm a low seroprevalence of SARS-CoV-2 exposure in companion animals in Korea and Hong Kong. The discordance between the RBD-ELISA and neutralization tests may indicate possible ELISA cross-reactivity with other coronaviruses, especially in canine sera.

Citing Articles

SARS-CoV-2 exposure in hunting and stray dogs of southern Italy.

Ferrara G, Pagnini U, Montagnaro S Vet Res Commun. 2024; 48(6):4037-4042.

PMID: 39167256 PMC: 11538181. DOI: 10.1007/s11259-024-10496-9.


Detection of SARS-CoV-2 Delta Variant (B.1.617.2) in Domestic Dogs and Zoo Tigers in England and Jersey during 2021.

Seekings A, Shipley R, Byrne A, Shukla S, Golding M, Amaya-Cuesta J Viruses. 2024; 16(4).

PMID: 38675958 PMC: 11053977. DOI: 10.3390/v16040617.


SARS-CoV-2 surveillance in a veterinary health system provides insight into transmission risks.

Sparrer M, Hodges N, Ragan I, Yamashita T, Reed K, Sherman T J Am Vet Med Assoc. 2023; 262(1):93-99.

PMID: 38103381 PMC: 11234244. DOI: 10.2460/javma.23.05.0229.


Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan.

Yamayoshi S, Ito M, Iwatsuki-Horimoto K, Yasuhara A, Okuda M, Hamabata T One Health. 2023; 17:100588.

PMID: 37359748 PMC: 10279464. DOI: 10.1016/j.onehlt.2023.100588.


SARS-CoV-2 Infection and Clinical Signs in Cats and Dogs from Confirmed Positive Households in Germany.

Michelitsch A, Allendorf V, Conraths F, Gethmann J, Schulz J, Wernike K Viruses. 2023; 15(4).

PMID: 37112817 PMC: 10144952. DOI: 10.3390/v15040837.

References
1.
Michelitsch A, Hoffmann D, Wernike K, Beer M . Occurrence of Antibodies against SARS-CoV-2 in the Domestic Cat Population of Germany. Vaccines (Basel). 2020; 8(4). PMC: 7766304. DOI: 10.3390/vaccines8040772. View

2.
de Wit E, van Doremalen N, Falzarano D, Munster V . SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523-34. PMC: 7097822. DOI: 10.1038/nrmicro.2016.81. View

3.
Donnik I, Popov I, Sereda S, Popov I, Chikindas M, Ermakov A . Coronavirus Infections of Animals: Future Risks to Humans. Biol Bull Russ Acad Sci. 2021; 48(1):26-37. PMC: 7917535. DOI: 10.1134/S1062359021010052. View

4.
Klaus J, Meli M, Willi B, Nadeau S, Beisel C, Stadler T . Detection and Genome Sequencing of SARS-CoV-2 in a Domestic Cat with Respiratory Signs in Switzerland. Viruses. 2021; 13(3). PMC: 8002591. DOI: 10.3390/v13030496. View

5.
Dileepan M, Di D, Huang Q, Ahmed S, Heinrich D, Ly H . Seroprevalence of SARS-CoV-2 (COVID-19) exposure in pet cats and dogs in Minnesota, USA. Virulence. 2021; 12(1):1597-1609. PMC: 8205054. DOI: 10.1080/21505594.2021.1936433. View